V.ISC.2601 - NLIS QA Test Automation and Improvement Online Summary

Summary

This report summarises the quality assurance verification completed across the NLIS platform for the period ending August 2026. Testing spanned nine workstreams covering the full NLIS transaction lifecycle — device status, hormone programs, platform migration, analytics, production defect resolution and infrastructure work. Coverage was applied through four testing types: functional (feature behaviour against acceptance criteria), regression (downstream reports and existing transaction paths), integration (Early Warning, Nimbus endpoints and Power BI embedding) and UAT support (business validation prior to production deployment). Every workstream in scope was tested and its behaviour confirmed, with seven production defects resolved and validated during the period.

Objectives

The testing programme set out to:

• Verify the Oestradiol Device Status implementation end to end across the full NLIS transaction lifecycle — ERP status, tag upload, transfers, movements, kill transactions, reporting and Early Warning — including re-testing of in-flight change requests and refactored stored procedures.
• Confirm the HOS (Hormone Sanctions) and HGP (Hormone Growth Promotant) status codes behave correctly in ERP Status of a Property and through all downstream reports and Early Warning processing.
• Validate the RunUploader-to-Nimbus migration, including feature-flag switchover in both states and continued legacy compatibility during transition.
  Verify sheep and goat individual movement handling and kill transaction validation (including ErrorID 1007 for unregistered and unauthorised establishment numbers).
• Confirm NLIS analytics and reporting changes across Power BI configuration, report embedding and access.
• Validate the resolution of seven production defects.
• Verify the infrastructure and system work, including the .NET 8 upgrade, logging, deadlock resolution and PENDING transaction redrives.
• Complete UAT integration testing prior to production deployment.

Key findings

All nine workstreams in scope were tested and their behaviour confirmed.
Oestradiol Device Status was verified end to end (25+ stories, 400+ test cases), with change requests and refactored stored procedures re-tested and UAT integration testing completed prior to production deployment.

Both hormone programs (HOS and HGP) were validated in ERP Status of a Property, across all downstream reports and through Early Warning — including the edge cases of "Clear No Test" suppression for accredited PICs (HOS) and correct exclusion of HGP from displays where not required.

The RunUploader-to-Nimbus migration was confirmed, with enquiry redirection, feature-flag switchover in both directions, endpoint changes with audit logging, and legacy endpoints remaining functional during transition.

Sheep and goat individual movement (auto-selection, Goat Depot access, new Breeder EID tag colours) and kill transaction validation (ErrorID 1007 firing correctly, leading-zero cancellation) were verified.

NLIS analytics and reporting changes were validated — Power BI configuration, the new usage-tracking table, Geolocation Multiple PIC Search embedding, Compliance Dashboard removal and expanded Processor Feedback access for AQISPlant users.

Seven production defects were resolved and validated, spanning scheduled jobs, file handling, upload paths and reporting.

Infrastructure and system work was verified, including the .NET 8 upgrade, lower-environment obfuscation, the PIC-Search Indexer fix, SNS logging, the quarterly File Rearrange restructure, deadlock resolutions and PENDING transaction redrives.

Benefits to industry

Stronger traceability integrity. Verifying Oestradiol Device Status end to end across the full transaction lifecycle — ERP status, tag upload, transfers, movements, kills, reporting and Early Warning — reinforces the accuracy of the national traceability data that producers, processors and regulators depend on for rapid biosecurity and residue response.

Protected market access. Validating the HGP and HOS hormone program status codes through ERP Status of a Property, all downstream reports and Early Warning helps ensure animal status is represented correctly — underpinning compliance and eligibility for premium and export markets, including HGP-sensitive markets.
Greater food safety and compliance assurance. Confirming ErrorID 1007 correctly rejects unregistered and unauthorised establishment numbers on kill transactions strengthens the controls that keep non-compliant establishments out of the processing chain.

More reliable industry data and reporting. Validated Power BI configuration, the new usage-tracking table, report embedding and expanded Processor Feedback access give industry users and regulators trustworthy analytics to support day-to-day and strategic decisions.

Improved platform stability and continuity. The .NET 8 upgrade, deadlock resolutions, PENDING transaction redrives and the RunUploader-to-Nimbus migration (delivered behind a feature flag with legacy compatibility) reduce the risk of disruption for the many users who transact on NLIS daily.